Abstract 15719: Right Ventricular Dysfunction After Transcatheter Aortic Valve Replacement (TAVR)
Background: Transcatheter aortic valve replacement (TAVR) is an alternative to surgical aortic valve replacement in patients at high surgical risk. We investigated the impact of TAVR on left (LV) and right ventricular (RV) function using conventional echocardiography parameters.
Methods and results: A total of 202 consecutive patients (age 80.6±8.0 years, aortic valve area 0.80±0.16cm2) who underwent TAVR at Mayo Clinic between 2008 and 2013 were included in the study. LV ejection fraction (EF) and RV systolic function including tricuspid annular plane systolic excursion (TAPSE), fractional area change (FAC) and, systolic excursion velocity (S’) were compared before (median 33.5 days) and after TAVR procedure (median 30 days). Patients who underwent pacemaker implantation after TAVR were excluded. LV EF significantly improved following TAVR (55.3±12.6% pre vs 58.5±11.1% post; p<0.05). In contrast, RV systolic function significantly decreased after TAVR (pre vs post; TAPSE: 18.8±6.3 mm vs 17.4±6.3 mm, FAC: 42.6±9.8% vs 37.3±8.2%; S’: 10.7±2.6 cm/s vs 10.2±2.6 cm/s; p<0.05 for all). Stratifying RV functional change by TAVR approach site, patients undergoing trans-femoral TAVR (n=100) showed RV deterioration only by FAC (see Table). In contrast, RV systolic dysfunction was more prominent in trans-apical approach group (n=87) with significant decline in all parameters of RV systolic function (see Table).
Conclusion: TAVR is associated with early enhancement in LV systolic function. However, there is evidence of worsening RV function in a significant number of patients. Further studies are necessary to determine whether this deterioration in RV function is related to anatomic access site or to other factors, and to evaluate its prognostic significance.
Author Disclosures: S. Ito: None. S.V. Pislaru: None. V.T. Nkomo: None. J.K. Oh: None. K.L. Greason: None. V. Mathew: None. D.R. Holmes: None. C.S. Rihal: None. R.M. Suri: Research Grant; Modest; Sorin, Edwards, Abbott, St.Jude. Consultant/Advisory Board; Modest; Abboot-COAPT trial, St.Jude-PORTICO trial, National PI for the Perceval Trial (Sorin), Co-Principal Investigator for the COAPT trial (Abbott). Other; Modest; Patents: Perceval Trial-Sorin-Patent applications.
- © 2014 by American Heart Association, Inc.